Table 1.

Clinicopathological parameters of WHOest, WHOnew, and ICCnew

MP-WHOest
n = 551 
MD-WHOest
n = 654 
WHOnew
n = 356 
q value MD-WHOest vs WHOnewICCnew
n = 241 
q value MD-WHOest vs ICCnew
Age, y 74.3 ± 8.6; 76.3 (37.8-93.3) 74.3 ± 9.1; 75.6 (19.9-92.7) 74.2 ± 9.3; 75.9 (30.8-91.9) 0.9 75.3 ± 8.1; 76.8 (43.8-91.9) 0.12 
Sex    0.2  0.3 
Female 171/551 (31%) 171/654 (26%) 107/356 (30%)  71/241 (29%)  
Male 380/551 (69%) 483/654 (74%) 249/356 (70%)  170/241 (71%)  
Clinical status       
First diagnosis 551/551 (100%) 654/654 (100%) 356/356 (100%)  241/241 (100%)  
Absolute monocyte count (PB), per nL 9371.7 ± 12 137.4; 5667.0 (1240.0-95 680.0) 1971.4 ± 1061.1; 1622.5 (1000.0-8160.0) 709.3 ± 140.0; 694.5 (500.0-998.4) <0.001 713.9 ± 138.5; 704.0 (500.0-998.4) <0.001 
% Monocytes (PB) 26.7 ± 13.2; 24.0 (10.0-79.0) 28.1 ± 11.2; 26.0 (10.0-70.0) 16.2 ± 6.4; 14.0 (10.0-46.0) <0.001 16.6 ± 6.4; 15.0 (10.0-43.0) <0.001 
White blood count, per nL 35 358.9 ± 33 350.0; 24 800.0 (13 000.0-370 580.0) 7171.5 ± 2845.8; 6850.0 (750.0-12 990.0) 4856.4 ± 1687.5; 4700.0 (1500.0-9960.0) <0.001 4786.7 ± 1704.7; 4600.0 (1500.0-9960.0) <0.001 
Hemoglobin, g/dL 10.9 ± 2.3; 10.9 (4.0-18.7) 11.3 ± 2.3; 11.2 (4.3-19.6) 10.7 ± 2.2; 10.6 (4.3-19.6) <0.001 10.5 ± 2.0; 10.3 (4.3-16.3) <0.001 
HB <9 g/dL (transfusion dependency) 96/546 (18%) 95/649 (15%) 54/349 (15%) 0.7 43/238 (18%) 0.2 
Platelets (per nL) 168 240.9 ± 196 848.4; 114 500.0 (4000.0-1 809 000.0) 138 521.6 ± 123 464.7; 108 000.0 (4000.0-1 385 000.0) 197 412.6 ± 151 556.8; 148 000.0 (4000.0-988 000.0) <0.001 196 071.4 ± 161 420.0; 138 000.0 (4000.0-988 000.0) <0.001 
Absolute neutrophil count (PB, per nL) 17 228.5 ± 16 322.8; 12 266.5 (1400.0-138 250.0) 3316.8 ± 2053.3; 2866.5 (180.0-9144.0) 2509.7 ± 1370.8; 2355.0 (124.8-7669.2) <0.001 2463.8 ± 1412.3; 2172.5 (136.8-7669.2) <0.001 
% Neutrophils (PB) 52.5 ± 14.8; 54.0 (8.0-82.0) 42.4 ± 15.6; 43.0 (5.0-79.0) 48.9 ± 15.2; 50.0 (6.0-80.0) <0.001 48.5 ± 15.4; 49.0 (6.0-80.0) <0.001 
Cytopenic lineages    <0.001  <0.001 
31/551 (5.6%) 28/654 (4.3%) 13/352 (3.7%)  0/241 (0%)  
257/551 (47%) 299/654 (46%) 157/352 (45%)  112/241 (46%)  
262/551 (48%) 284/654 (43%) 120/352 (34%)  81/241 (34%)  
1/551 (0.2%) 43/654 (6.6%) 62/352 (18%)  48/241 (20%)  
% blasts (PB) 1.2 ± 2.2; 0.0 (0.0-12.0) 0.4 ± 1.4; 0.0 (0.0-14.0) 0.2 ± 1.1; 0.0 (0.0-11.0) <0.001 0.3 ± 1.2; 0.0 (0.0-11.0) 0.002 
% blasts (BM) 7.0 ± 5.0; 6.0 (0.0-19.5) 6.3 ± 4.1; 5.5 (0.0-19.5) 4.0 ± 3.5; 3.0 (0.0-18.0) <0.001 4.4 ± 3.7; 3.5 (0.0-18.0) <0.001 
Blasts in PB and BM    <0.001  <0.001 
<2% PB blasts and <5% BM blasts 203/551 (37%) 258/654 (39%) 256/356 (72%)  164/241 (68%)  
≥2% and <10% PB blasts or ≥5% and <10% BM blasts 202/551 (37%) 275/654 (42%) 72/356 (20%)  57/241 (24%)  
≥10% and <20% PB blasts or ≥10% and <20% BM blasts 146/551 (26%) 121/654 (19%) 28/356 (7.9%)  20/241 (8.3%)  
Percentage of monocytes (BM), % 15.9 ± 11.6; 13.0 (0.0-77.5) 13.9 ± 10.3; 12.0 (0.0-77.0) 4.7 ± 4.5; 3.5 (0.0-38.5) <0.001 4.2 ± 4.1; 3.0 (0.0-31.0) <0.001 
Ringsideroblasts (BM, in %) 3.7 ± 12.1; 0.0 (0.0-89.0) 7.7 ± 19.8; 0.0 (0.0-96.0) 20.6 ± 30.2; 0.0 (0.0-97.0) <0.001 23.6 ± 31.8; 1.0 (0.0-97.0) <0.001 
Esterase positivity (BM, in %) 19.7 ± 14.7; 20.0 (0.0-80.0) 16.2 ± 13.3; 15.0 (0.0-70.0) 6.6 ± 9.9; 0.0 (0.0-60.0) <0.001 7.1 ± 10.5; 0.0 (0.0-60.0) <0.001 
Cellularity (BM)    <0.001  <0.001 
Hypercellular 474/551 (86%) 506/654 (77%) 250/356 (70%)  241/241 (100%)  
Hypocellular 21/551 (3.8%) 67/654 (10%) 24/356 (6.7%)  0/241 (0%)  
Normal 56/551 (10%) 81/654 (12%) 82/356 (23%)  0/241 (0%)  
Dysplastic lineages (BM)    <0.001  0.004 
112/551 (20%) 81/654 (12%) 0/356 (0%)  12/241 (5.0%)  
167/551 (30%) 141/654 (22%) 93/356 (26%)  45/241 (19%)  
161/551 (29%) 230/654 (35%) 132/356 (37%)  88/241 (37%)  
111/551 (20%) 202/654 (31%) 131/356 (37%)  96/241 (40%)  
Karyotype risk score    <0.001  <0.001 
431/551 (78%) 560/654 (86%) 258/356 (72%)  177/241 (73%)  
54/551 (9.8%) 45/654 (6.9%) 47/356 (13%)  28/241 (12%)  
66/551 (12%) 49/654 (7.5%) 51/356 (14%)  36/241 (15%)  
Molecular risk score    0.077  0.11 
84/390 (22%) 262/531 (49%) 143/246 (58%)  91/158 (58%)  
105/390 (27%) 112/531 (21%) 44/246 (18%)  26/158 (16%)  
81/390 (21%) 68/531 (13%) 32/246 (13%)  24/158 (15%)  
120/390 (31%) 89/531 (17%) 27/246 (11%)  17/158 (11%)  
CPSS-Mol (complete observations)    <0.001  0.029 
Low 0/429 (0%) 113/543 (21%) 95/256 (37%)  54/168 (32%)  
Intermediate 1 37/429 (8.6%) 172/543 (32%) 70/256 (27%)  46/168 (27%)  
Intermediate 2 180/429 (42%) 191/543 (35%) 68/256 (27%)  53/168 (32%)  
High 212/429 (49%) 67/543 (12%) 23/256 (9.0%)  15/168 (8.9%)  
CPSS (complete observations)    0.021  0.012 
Low 0/548 (0%) 401/650 (62%) 198/349 (57%)  133/238 (56%)  
Intermediate 1 282/548 (51%) 173/650 (27%) 90/349 (26%)  61/238 (26%)  
Intermediate 2 227/548 (41%) 69/650 (11%) 60/349 (17%)  44/238 (18%)  
High 39/548 (7.1%) 7/650 (1.1%) 1/349 (0.3%)  0/238 (0%)  
Mean IPSS-M       
Very low   52/356 (15%)  22/241 (9.1%)  
Low   165/356 (46%)  113/241 (47%)  
Moderate low   51/356 (14%)  42/241 (17%)  
Moderate high   32/356 (9.0%)  21/241 (8.7%)  
High   35/356 (9.8%)  25/241 (10%)  
Very high   21/356 (5.9%)  18/241 (7.5%)  
IPSS-R       
Very low   77/348 (22%)  45/237 (19%)  
Low   162/348 (47%)  109/237 (46%)  
Intermediate   68/348 (20%)  53/237 (22%)  
High   33/348 (9.5%)  25/237 (11%)  
Very high   8/348 (2.3%)  5/237 (2.1%)  
MP-WHOest
n = 551 
MD-WHOest
n = 654 
WHOnew
n = 356 
q value MD-WHOest vs WHOnewICCnew
n = 241 
q value MD-WHOest vs ICCnew
Age, y 74.3 ± 8.6; 76.3 (37.8-93.3) 74.3 ± 9.1; 75.6 (19.9-92.7) 74.2 ± 9.3; 75.9 (30.8-91.9) 0.9 75.3 ± 8.1; 76.8 (43.8-91.9) 0.12 
Sex    0.2  0.3 
Female 171/551 (31%) 171/654 (26%) 107/356 (30%)  71/241 (29%)  
Male 380/551 (69%) 483/654 (74%) 249/356 (70%)  170/241 (71%)  
Clinical status       
First diagnosis 551/551 (100%) 654/654 (100%) 356/356 (100%)  241/241 (100%)  
Absolute monocyte count (PB), per nL 9371.7 ± 12 137.4; 5667.0 (1240.0-95 680.0) 1971.4 ± 1061.1; 1622.5 (1000.0-8160.0) 709.3 ± 140.0; 694.5 (500.0-998.4) <0.001 713.9 ± 138.5; 704.0 (500.0-998.4) <0.001 
% Monocytes (PB) 26.7 ± 13.2; 24.0 (10.0-79.0) 28.1 ± 11.2; 26.0 (10.0-70.0) 16.2 ± 6.4; 14.0 (10.0-46.0) <0.001 16.6 ± 6.4; 15.0 (10.0-43.0) <0.001 
White blood count, per nL 35 358.9 ± 33 350.0; 24 800.0 (13 000.0-370 580.0) 7171.5 ± 2845.8; 6850.0 (750.0-12 990.0) 4856.4 ± 1687.5; 4700.0 (1500.0-9960.0) <0.001 4786.7 ± 1704.7; 4600.0 (1500.0-9960.0) <0.001 
Hemoglobin, g/dL 10.9 ± 2.3; 10.9 (4.0-18.7) 11.3 ± 2.3; 11.2 (4.3-19.6) 10.7 ± 2.2; 10.6 (4.3-19.6) <0.001 10.5 ± 2.0; 10.3 (4.3-16.3) <0.001 
HB <9 g/dL (transfusion dependency) 96/546 (18%) 95/649 (15%) 54/349 (15%) 0.7 43/238 (18%) 0.2 
Platelets (per nL) 168 240.9 ± 196 848.4; 114 500.0 (4000.0-1 809 000.0) 138 521.6 ± 123 464.7; 108 000.0 (4000.0-1 385 000.0) 197 412.6 ± 151 556.8; 148 000.0 (4000.0-988 000.0) <0.001 196 071.4 ± 161 420.0; 138 000.0 (4000.0-988 000.0) <0.001 
Absolute neutrophil count (PB, per nL) 17 228.5 ± 16 322.8; 12 266.5 (1400.0-138 250.0) 3316.8 ± 2053.3; 2866.5 (180.0-9144.0) 2509.7 ± 1370.8; 2355.0 (124.8-7669.2) <0.001 2463.8 ± 1412.3; 2172.5 (136.8-7669.2) <0.001 
% Neutrophils (PB) 52.5 ± 14.8; 54.0 (8.0-82.0) 42.4 ± 15.6; 43.0 (5.0-79.0) 48.9 ± 15.2; 50.0 (6.0-80.0) <0.001 48.5 ± 15.4; 49.0 (6.0-80.0) <0.001 
Cytopenic lineages    <0.001  <0.001 
31/551 (5.6%) 28/654 (4.3%) 13/352 (3.7%)  0/241 (0%)  
257/551 (47%) 299/654 (46%) 157/352 (45%)  112/241 (46%)  
262/551 (48%) 284/654 (43%) 120/352 (34%)  81/241 (34%)  
1/551 (0.2%) 43/654 (6.6%) 62/352 (18%)  48/241 (20%)  
% blasts (PB) 1.2 ± 2.2; 0.0 (0.0-12.0) 0.4 ± 1.4; 0.0 (0.0-14.0) 0.2 ± 1.1; 0.0 (0.0-11.0) <0.001 0.3 ± 1.2; 0.0 (0.0-11.0) 0.002 
% blasts (BM) 7.0 ± 5.0; 6.0 (0.0-19.5) 6.3 ± 4.1; 5.5 (0.0-19.5) 4.0 ± 3.5; 3.0 (0.0-18.0) <0.001 4.4 ± 3.7; 3.5 (0.0-18.0) <0.001 
Blasts in PB and BM    <0.001  <0.001 
<2% PB blasts and <5% BM blasts 203/551 (37%) 258/654 (39%) 256/356 (72%)  164/241 (68%)  
≥2% and <10% PB blasts or ≥5% and <10% BM blasts 202/551 (37%) 275/654 (42%) 72/356 (20%)  57/241 (24%)  
≥10% and <20% PB blasts or ≥10% and <20% BM blasts 146/551 (26%) 121/654 (19%) 28/356 (7.9%)  20/241 (8.3%)  
Percentage of monocytes (BM), % 15.9 ± 11.6; 13.0 (0.0-77.5) 13.9 ± 10.3; 12.0 (0.0-77.0) 4.7 ± 4.5; 3.5 (0.0-38.5) <0.001 4.2 ± 4.1; 3.0 (0.0-31.0) <0.001 
Ringsideroblasts (BM, in %) 3.7 ± 12.1; 0.0 (0.0-89.0) 7.7 ± 19.8; 0.0 (0.0-96.0) 20.6 ± 30.2; 0.0 (0.0-97.0) <0.001 23.6 ± 31.8; 1.0 (0.0-97.0) <0.001 
Esterase positivity (BM, in %) 19.7 ± 14.7; 20.0 (0.0-80.0) 16.2 ± 13.3; 15.0 (0.0-70.0) 6.6 ± 9.9; 0.0 (0.0-60.0) <0.001 7.1 ± 10.5; 0.0 (0.0-60.0) <0.001 
Cellularity (BM)    <0.001  <0.001 
Hypercellular 474/551 (86%) 506/654 (77%) 250/356 (70%)  241/241 (100%)  
Hypocellular 21/551 (3.8%) 67/654 (10%) 24/356 (6.7%)  0/241 (0%)  
Normal 56/551 (10%) 81/654 (12%) 82/356 (23%)  0/241 (0%)  
Dysplastic lineages (BM)    <0.001  0.004 
112/551 (20%) 81/654 (12%) 0/356 (0%)  12/241 (5.0%)  
167/551 (30%) 141/654 (22%) 93/356 (26%)  45/241 (19%)  
161/551 (29%) 230/654 (35%) 132/356 (37%)  88/241 (37%)  
111/551 (20%) 202/654 (31%) 131/356 (37%)  96/241 (40%)  
Karyotype risk score    <0.001  <0.001 
431/551 (78%) 560/654 (86%) 258/356 (72%)  177/241 (73%)  
54/551 (9.8%) 45/654 (6.9%) 47/356 (13%)  28/241 (12%)  
66/551 (12%) 49/654 (7.5%) 51/356 (14%)  36/241 (15%)  
Molecular risk score    0.077  0.11 
84/390 (22%) 262/531 (49%) 143/246 (58%)  91/158 (58%)  
105/390 (27%) 112/531 (21%) 44/246 (18%)  26/158 (16%)  
81/390 (21%) 68/531 (13%) 32/246 (13%)  24/158 (15%)  
120/390 (31%) 89/531 (17%) 27/246 (11%)  17/158 (11%)  
CPSS-Mol (complete observations)    <0.001  0.029 
Low 0/429 (0%) 113/543 (21%) 95/256 (37%)  54/168 (32%)  
Intermediate 1 37/429 (8.6%) 172/543 (32%) 70/256 (27%)  46/168 (27%)  
Intermediate 2 180/429 (42%) 191/543 (35%) 68/256 (27%)  53/168 (32%)  
High 212/429 (49%) 67/543 (12%) 23/256 (9.0%)  15/168 (8.9%)  
CPSS (complete observations)    0.021  0.012 
Low 0/548 (0%) 401/650 (62%) 198/349 (57%)  133/238 (56%)  
Intermediate 1 282/548 (51%) 173/650 (27%) 90/349 (26%)  61/238 (26%)  
Intermediate 2 227/548 (41%) 69/650 (11%) 60/349 (17%)  44/238 (18%)  
High 39/548 (7.1%) 7/650 (1.1%) 1/349 (0.3%)  0/238 (0%)  
Mean IPSS-M       
Very low   52/356 (15%)  22/241 (9.1%)  
Low   165/356 (46%)  113/241 (47%)  
Moderate low   51/356 (14%)  42/241 (17%)  
Moderate high   32/356 (9.0%)  21/241 (8.7%)  
High   35/356 (9.8%)  25/241 (10%)  
Very high   21/356 (5.9%)  18/241 (7.5%)  
IPSS-R       
Very low   77/348 (22%)  45/237 (19%)  
Low   162/348 (47%)  109/237 (46%)  
Intermediate   68/348 (20%)  53/237 (22%)  
High   33/348 (9.5%)  25/237 (11%)  
Very high   8/348 (2.3%)  5/237 (2.1%)  

BM, bone marrow; HB, hemoglobin; PB, peripheral blood; SD, standard deviation,

n / N (%); mean ± SD; median (range).

Pearson χ2 test; Wilcoxon rank sum test; and Fisher exact test after false discovery rate correction for multiple testing.

Close Modal

or Create an Account

Close Modal
Close Modal